Speaker Nancy Pelosi (D-CA) unveiled her long-awaited, sweeping “Lower Drug Costs Now Act of 2019” (HR 3) that would establish price controls for up to 250 branded drugs, not just for government programs, but for all commercial contracts as well!
Walter Klemp, CEO of Moleculin, shares several lessons he learned from his consumer-product background.
This month’s company to watch is eXIthera, which is focused on inhibiting Factor XIa, a new target that may offer a way to avoid the bleeding problems with current anticoagulants.
Organizations and their leaders often focus on what needs to improve, but research shows there is more to be gained from a strengths-based approach. Coaching around strengths yields greater optimism and success.
Curative cell & gene therapies are changing modern medicine as we know it, but are their high price tags fair to the patient?
Catherine Clark, a professor at Duke University specializing in impact investing, provides six pieces of wisdom for those considering becoming impact investors.
Matt Patterson, chairman and CEO of Audentes Therapeutics, provides perspective on what it’s like being the CEO of a startup biopharmaceutical company. Spoiler alert, it isn’t all glitz and glam.
Matt Patterson, chairman and CEO of Audentes Therapeutics, discusses the experiences that best prepared him for being the CEO of a biopharmaceutical company, including brushes with industry icon Henri Termeer.
